VaxcytePCVX
PCVX
0
Funds holding %
of 6,780 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
254% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 24
66% more capital invested
Capital invested by funds: $9.31B [Q2] → $15.5B (+$6.15B) [Q3]
53% more funds holding in top 10
Funds holding in top 10: 15 [Q2] → 23 (+8) [Q3]
48% more call options, than puts
Call options by funds: $90.6M | Put options by funds: $61.4M
45% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 87
23% more funds holding
Funds holding: 263 [Q2] → 324 (+61) [Q3]
2.1% less ownership
Funds ownership: 113.26% [Q2] → 111.16% (-2.1%) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$129
41%
upside
Avg. target
$146
60%
upside
High target
$163
78%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Needham Joseph Stringer 27% 1-year accuracy 30 / 111 met price target | 53%upside $140 | Buy Reiterated | 6 Nov 2024 |
Mizuho Salim Syed 67% 1-year accuracy 10 / 15 met price target | 78%upside $163 | Outperform Maintained | 10 Sept 2024 |
B of A Securities Jason Gerberry 30% 1-year accuracy 6 / 20 met price target | 53%upside $140 | Buy Maintained | 4 Sept 2024 |
Leerink Partners David Risinger 56% 1-year accuracy 5 / 9 met price target | 67%upside $153 | Outperform Maintained | 3 Sept 2024 |
Jefferies Roger Song 31% 1-year accuracy 5 / 16 met price target | 41%upside $129 | Buy Maintained | 3 Sept 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 --
Neutral
GlobeNewsWire
3 weeks ago
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase 3 Pivotal, Non-Inferiority Study Expected by Mid-2025 and Announcement of Topline Safety, Tolerability and Immunogenicity Data in 2026 --
Neutral
GlobeNewsWire
2 months ago
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.
Positive
Seeking Alpha
2 months ago
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025.
Neutral
GlobeNewsWire
2 months ago
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,893,203 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $1.5 billion, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
Positive
Seeking Alpha
2 months ago
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market.
Negative
Market Watch
2 months ago
Vaxcyte's stock dips after biotech completes $1.42 billion stock offering
Vaxcyte Inc.'s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 billion in proceeds.
Positive
Reuters
2 months ago
Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high
Vaxcyte , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high on promising results in a vaccine trial.
Neutral
GlobeNewsWire
2 months ago
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,893,203 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
Positive
Zacks Investment Research
2 months ago
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.
Charts implemented using Lightweight Charts™